Henrik Johansson

Henrik Johansson

Auto-generated profile, based on publicly available information

Henrik Johansson

Novo Nordisk A/S, CMC API Development, DK-2880 Bagsværd, Denmark

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2020 in RSC Advances
Verified
Journal Article
Open access
PDF file
VMVincent Martin
Vincent Martin
PEPeter H. G. Egelund
Peter H. G. Egelund
HJHenrik Johansson
Henrik Johansson
SQSebastian Thordal Le Quement
Sebastian Thordal Le Quement
FWFelix Wojcik
Felix Wojcik
DPDaniel Sejer Pedersen
Daniel Sejer Pedersen
This review highlights the efforts made to date to promote greener peptide synthesis, from an industrial perspective.

18 January 2019 in Journal of the American Chemical Society
Verified
Journal Article
Open access
HJHenrik Johansson
Henrik Johansson
YTYi-Chun Isabella Tsai
Yi-Chun Isabella Tsai
KFKen Fantom
Ken Fantom
CCChun-Wa Chung
Chun-Wa Chung
SKSandra Kümper
Sandra Kümper
KRKatrin Rittinger
Katrin Rittinger
Modification of proteins with polyubiquitin chains is a key regulatory mechanism to control cellular behavior and altera-tions in the ubiquitin system are linked to many diseases. Linear (M1-linked) polyubiquitin chains play pivotal roles in several cellular signalling pathways mediating immune and inflammatory responses and apoptotic cell death. These chains are formed by the linear ubiquitin chain assembly complex (LUBAC), a multi-protein E3 ligase that consists of 3 subunits, HOIP, HOIL-1L and SHARPIN. Herein, we describe the discovery of inhibitors targeting the active site cysteine of the catalytic subunit HOIP using fragment-based covalent ligand screening. We report the synthesis of a diverse library of electrophilic fragments and demonstrate an integrated use of protein LC-MS, biochemical ubiquitination assays, chemi-cal synthesis and protein crystallography to enable the first structure-based development of covalent inhibitors for an RBR E3 ligase. Furthermore, using cell-based assays and chemoproteomics we demonstrate that these compounds effec-tively penetrate mammalian cells to label and inhibit HOIP and NF-κB activation, making them suitable hits for the devel-opment of selective probes to study LUBAC biology. Our results illustrate the power of fragment-based covalent ligand screening to discover lead compounds for challenging targets, which holds promise to be a general approach for the de-velopment of cell-permeable inhibitors of thioester-forming E3 ubiquitin ligases.

7 April 2021 in Green Chemistry
Verified
Journal Article
Open access
PDF file
VMVincent Martin
Vincent Martin
SJSandip Jadhav
Sandip Jadhav
PEPeter H. G. Egelund
Peter H. G. Egelund
RLRaphael Liffert
Raphael Liffert
HCHenrik Johansson Castro
Henrik Johansson Castro
DPDaniel Sejer Pedersen
Daniel Sejer Pedersen
Solid-phase peptide synthesis (SPPS) enables routine synthesis of virtually any type of peptide sequence and is the preferred method for peptide synthesis in academia and the pharmaceutical industry alike. Still, SPPS typically requires significant amounts of hazardous solvents and thus suffers from a negative environmental footprint. Such drawbacks have spurred numerous initiatives for solvent substitution, reduction and recycling, and a handful solvents have recently been proposed as potential green alternatives to N,N-dimethylformamide (DMF). In this report, we recognise solvent viscosity and polarity in combination as key physicochemical parameters for SPPS and identify green binary solvent mixtures of dimethyl sulfoxide (DMSO) and 1,3-dioxolane or 2-methyl tetrahydrofuran that closely resemble DMF. In a series of reagent dissolution, resin swelling, peptide coupling and Fmoc-removal experiments we show that combining solvents offers unprecedented opportunities to predict and fine-tune the overall solvent properties for different aspects of SPPS. Lastly, the identified green binary solvent mixtures were employed for the synthesis of a range of challenging model peptides and peptide therapeutics on meaningful scale, demonstrating that binary solvent mixtures are viable green alternatives to DMF in SPPS.

19 April 2021 in Green Chemistry
Verified
Journal Article
Open access
PDF file
SJSandip Jadhav
Sandip Jadhav
VMVincent Martin
Vincent Martin
PEPeter H. G. Egelund
Peter H. G. Egelund
HCHenrik Johansson Castro
Henrik Johansson Castro
TKTobias Krüger
Tobias Krüger
DPDaniel Sejer Pedersen
Daniel Sejer Pedersen
Significant efforts have been made in recent years to identify more environmentally benign and less hazardous alternatives to N,N-dimethylformamide (DMF) in solid-phase peptide synthesis (SPPS). Several greener solvents have been endorsed as suitable candidates yet finding a neat solvent that fully matches the qualities of DMF in SPPS has proven challenging. To this end, we recently demonstrated that green binary solvent mixtures are viable alternatives to DMF and showed that the polarity and viscosity profile of a binary solvent mixture can be used to predict its utility in SPPS. In this report, we systematically investigate how the composition of green binary solvent mixtures influences Fmoc-removal, peptide coupling and common side-reactions in SPPS and show that the purity profile is not impacted adversely in binary solvent mixtures when compared to DMF. Furthermore, we demonstrate that the sole variation of the composition of the binary solvent mixture during synthesis represents a novel and simple tool to mitigate certain side-reactions in SPPS, exemplified by suppression of Arg-lactamisation and aspartimide formation. When applied to the synthesis of the peptide therapeutic Bivalirudin on a 7.5 mmol scale, we showed that simply adjusting the solvent ratio in a single step of the synthesis significantly suppressed a problematic Arg-lactamisation side-reaction. These results underline that green binary solvent mixtures not only can replace DMF in SPPS but also provide novel solutions for mitigating common side-reactions in SPPS.

1 January 2020 in Cell Chemical Biology
Verified
Journal Article
Open access
YTYi-Chun Isabella Tsai
Yi-Chun Isabella Tsai
HJHenrik Johansson
Henrik Johansson
DDDavid Dixon
David Dixon
SMStephen Martin
Stephen Martin
CCChun-Wa Chung
Chun-Wa Chung
KRKatrin Rittinger
Katrin Rittinger
Protein ubiquitination plays a key role in the regulation of cellular processes, and misregulation of the ubiquitin system is linked to many diseases. So far, development of tool compounds that target enzymes of the ubiquitin system has been slow and only a few specific inhibitors are available. Here, we report the selection of single-domain antibodies (single-dAbs) based on a human scaffold that recognize the catalytic domain of HOIP, a subunit of the multi-component E3 LUBAC and member of the RBR family of E3 ligases. Some of these dAbs affect ligase activity and provide mechanistic insight into the ubiquitin transfer mechanism of different E2-conjugating enzymes. Furthermore, we show that the co-crystal structure of a HOIP RBR/dAb complex serves as a robust platform for soaking of ligands that target the active site cysteine of HOIP, thereby providing easy access to structure-based ligand design for this important class of E3 ligases.

16 November 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HJHenrik Johansson
Henrik Johansson
MBMichael Worch Boesgaard
Michael Worch Boesgaard
LNLenea Nørskov-Lauritsen
Lenea Nørskov-Lauritsen
ILInna Larsen
Inna Larsen
SKSebastiaan Kuhne
Sebastiaan Kuhne
DPDaniel Sejer Pedersen
Daniel Sejer Pedersen